Contrasting Histogenics (HSGX) & Sientra (SIEN)

Histogenics (NASDAQ: HSGX) and Sientra (NASDAQ:SIEN) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, risk, earnings, profitability, analyst recommendations and valuation.

Analyst Ratings

How to Become a New Pot Stock Millionaire

This is a breakdown of current recommendations for Histogenics and Sientra, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Histogenics 0 0 2 0 3.00
Sientra 0 1 5 0 2.83

Histogenics currently has a consensus target price of $4.00, indicating a potential upside of 42.86%. Sientra has a consensus target price of $14.00, indicating a potential upside of 51.19%. Given Sientra’s higher probable upside, analysts plainly believe Sientra is more favorable than Histogenics.

Earnings and Valuation

This table compares Histogenics and Sientra’s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Histogenics N/A N/A -$26.41 million ($0.98) -2.86
Sientra $36.54 million 4.98 -$64.02 million ($2.82) -3.28

Histogenics has higher earnings, but lower revenue than Sientra. Sientra is trading at a lower price-to-earnings ratio than Histogenics, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Histogenics has a beta of 1.69, suggesting that its share price is 69% more volatile than the S&P 500. Comparatively, Sientra has a beta of -1.06, suggesting that its share price is 206% less volatile than the S&P 500.

Profitability

This table compares Histogenics and Sientra’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Histogenics N/A -658.91% -131.87%
Sientra -175.22% -107.35% -55.62%

Insider and Institutional Ownership

43.0% of Histogenics shares are held by institutional investors. Comparatively, 77.4% of Sientra shares are held by institutional investors. 23.8% of Histogenics shares are held by insiders. Comparatively, 28.1% of Sientra shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Sientra beats Histogenics on 7 of the 12 factors compared between the two stocks.

About Histogenics

Histogenics Corporation, a regenerative medicine company, focuses on developing and commercializing products in the musculoskeletal segment of the marketplace in the United States. The company offers NeoCart, a tissue implant, which is in Phase III clinical trial to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee. It has an exclusive channel collaboration agreement with Intrexon Corporation for the development and commercialization of allogeneic genetically modified chondrocyte cell therapeutics for the treatment or repair of damaged articular hyaline cartilage in humans. Histogenics Corporation was founded in 2000 and is headquartered in Waltham, Massachusetts.

About Sientra

Sientra, Inc., a medical aesthetics company, develops and sells medical aesthetics products to plastic surgeons in the United States. It operates through two segments, Breast Products and miraDry. The company offers silicone gel breast implants for use in breast augmentation and breast reconstruction procedures; breast tissue expanders; and scar management products under the Sientra, AlloX2, Dermaspan, Softspan, and BIOCORNEUM brand names. It also provides body contouring products; facial and nasal implants; saline-filled breast implant sizers to identify the correct style and size of implants; and non-breast tissue expanders for expanding tissue and skin surface area for burn care and other reconstructive use. The company was formerly known as Juliet Medical, Inc. and changed its name to Sientra, Inc. in April 2007. Sientra, Inc. was incorporated in 2003 and is headquartered in Santa Barbara, California.

Receive News & Ratings for Histogenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Histogenics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Brokerages Set National Commerce  Target Price at $44.25
Brokerages Set National Commerce Target Price at $44.25
Valero Energy Partners  Receives $48.67 Average Price Target from Analysts
Valero Energy Partners Receives $48.67 Average Price Target from Analysts
Transocean LTD  Given Average Rating of “Hold” by Analysts
Transocean LTD Given Average Rating of “Hold” by Analysts
BT2 [CST]  Trading Down 7.2% This Week
BT2 [CST] Trading Down 7.2% This Week
PACcoin Tops One Day Trading Volume of $195,225.00
PACcoin Tops One Day Trading Volume of $195,225.00
Frontier Communications  Bond Prices Rise 1%
Frontier Communications Bond Prices Rise 1%


Leave a Reply

© 2006-2018 Ticker Report. Google+.